ĐỊNH LƯỢNG VILDAGLIPTIN TRONG VIÊN NÉN BẰNG PHƯƠNG PHÁP SẮC KÝ LỎNG HIỆU NĂNG CAO
Thông tin bài báo
Ngày nhận bài: 05/04/23                Ngày hoàn thiện: 19/06/23                Ngày đăng: 19/06/23Tóm tắt
Từ khóa
Toàn văn:
PDF (English)Tài liệu tham khảo
[1] B. Ahrén, R. Gomis, E. Standl, D. Mills, and A. Schweizer, "Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes," Diabetes care, vol. 27, pp. 2874-2880, 2004.
[2] L. L. Baggio and D. J. Drucker, "Biology of incretins: GLP-1 and GIP," Gastroenterology, vol. 132, pp. 2131-2157, 2007.
[3] A. Lund, F. K. Knop, and T. Vilsbøll, "Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities," European journal of internal medicine, vol. 25, pp. 407-414, 2014.
[4] F. K. Saraiva and A. C. Sposito, "Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists," Cardiovascular Diabetology, vol. 13, pp. 1-11, 2014.
[5] S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, et al., "Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes," Diabetes care, vol. 38, pp. 140-149, 2015.
[6] D. Care, "Care in Diabetesd2019," Diabetes care, vol. 42, pp. S13-S28, 2019.
[7] S. E. Kahn, M. E. Cooper, and S. Del Prato, "Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future," The Lancet, vol. 383, pp. 1068-1083, 2014.
[8] A. T. Barden, B. L. Piccoli, N. M. Volpato, and M. Steppe, "Second-order derivative UV spectrophotometric and RP-HPLC methods for the analysis of vildagliptin and application for dissolution study," Drug Analytical Research, vol. 2, pp. 46-53, 2018.
[9] E. Uçaktürk, "Development of sensitive and specific analysis of vildagliptin in pharmaceutical formulation by gas chromatography-mass spectrometry," Journal of analytical methods in chemistry, vol. 2015, pp. 1-7, 2015.
[10] S. R. Butle and P. B. Deshpande, "Validated stability-indicating HPTLC method development for determination of vildagliptin as bulk drug and in tablet dosage form," in Conference on Harmonisation Guidelines, 2015, p. 18.
[11] M. Fadr, A. N. Amro, and S. B. Aoun, "Voltammetric determination of vildagliptin in a pharmaceutical formulation," Tropical Journal of Pharmaceutical Research, vol. 17, pp. 1847-1852, 2018.
[12] E. Al-Qudah, S. Arar, and K. Sweidan, "Forced degradation studies of vildagliptin raw material alone and in the presence of excipients using HPLC-UV analysis," Journal of Excipients and Food Chemicals, vol. 11, pp. 29-41, 2020.
[13] T. Boovizhikannan and V. K. Palanirajan, "RP-HPLC determination of vildagliptin in pure and in tablet formulation," Journal of pharmacy research, vol. 7, pp. 113-116, 2013.
[14] M. M. Chaphekar and P. D. Hamrapurkar, "Development and validation of RP-HPLC assay method for vildagliptin using QbD approach and its application to forced degradation studies," Int. J. Pharm. Sci. Drug Res, vol. 8, pp. 157-165, 2016.
[15] S. Huang and M. Zhang, "Determination of Related Substances in Vildagliptin Tablets by HPLC," China Pharmacy, vol. 12, pp. 2138-2141, 2017.
[16] R. Khatun and M. Mirazunnabi, "A validated reversed-phase HPLC method for the determination of vildagliptin from tablet dosage form," International Journal of Pharmaceutical and Life Sciences, vol. 2, pp. 90-98, 2013.
[17] V. V. Karkhanis and A. D. Captain, "Development and Validation of a Liquid Chromatographic Method for Estimation of Vildagliptin in Tablet Dosage Form," Asian Journal of Research in Chemistry, vol. 6, pp. 1166-1168, 2013.
[18] R. Sultana, S. C. Bachar, and F. Rahman, "Development and validation of stability indicating assay method of vildagliptin in bulk and tablet dosage form by RP-HPLC," International journal of pharmacy & life sciences, vol. 4, pp. 2530-2534, 2013.
[19] A. M. Yehia, M. R. El‐ghobashy, A. H. Helmy, and N. F. Youssef, "Chromatographic separation of vildagliptin and l‐proline as in‐process impurity with the application of Youden's test and statistical analysis to test the robustness of the HPLC method," Separation Science Plus, vol. 1, pp. 395-403, 2018.
[20] A. T. Barden, B. Salamon, E. E. S. Schapoval, and M. Steppe, "Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product," Journal of chromatographic science, vol. 50, pp. 426-432, 2012.DOI: https://doi.org/10.34238/tnu-jst.7680
Các bài báo tham chiếu
- Hiện tại không có bài báo tham chiếu